Bionovo, Inc. Announces Presentation On Its Lead Anti-Cancer Compound At Upcoming San Antonio Breast Cancer Symposium
EMERYVILLE, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Bionovo, Inc. today announced that a poster presentation providing phase 1 results of its drug BZL101, in breast cancer, will be made on December 8 at the 28th Annual San Antonio Breast Cancer Symposium, which is taking place December 8-11 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The presentation information is as follows:
Presentation Time: Thursday, December 8, 2005, 4:30 - 6:30 p.m. Location: Henry B. Gonzalez Convention Center, Exhibit Hall B Title: A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer (poster #1079)
BZL101 is an oral drug designed for the treatment of breast cancer and other solid tumors that targets only diseased cells, leaving the normal cells intact and functioning. BZL101 is a compound that induces apoptosis by translocating the mitochondrial transmembrane protein apoptosis inducing factor (AIF) into the nucleus of the cell, causing chromatin condensation and caspase independent DNA degradation that leads to the cell's death.
There are currently no effective therapeutic cures for advanced breast cancer and treatment is primarily aimed at palliation of symptoms as well as improving overall survival. Breast cancer is the second leading cause of cancer death with over 200,000 new cases per year. Although survival after breast cancer treatments is improving, there are still more than 40,000 deaths per year due to breast cancer.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs ready to enter Phase 2 clinical testing, one for breast cancer therapy and another to treat conditions associated with menopause. The company is developing its products in close collaboration with leading U.S. academic research centers including the University of California, San Francisco; University of Colorado Health Sciences Center; University of California, Berkeley; and The University of Texas, Southwestern Medical Center. For further information please visit: www.bionovo.com.
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third-party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated, or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission (SEC), which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
This release was issued through Major Newswire (http://www.majornewswire.com)Bionovo, Inc.
CONTACT: Jim Stapleton, Chief Financial Officer of Bionovo, Inc.,+1-510-601-2000, firstname.lastname@example.org; or Carolyn Bumgardner Wang of WeissCommPartners, +1-415-225-5050, email@example.com, for Bionovo, Inc.